
Clyde Biosciences
Meet Clyde Biosciences at the UK Pavilion (Hall B, Stand 2348).
Clyde Biosciences specialises in measuring and interpreting drug effects on cardiac cell function at clinically relevant doses. The company's proprietary technology combines a rang of human stem cell and other relevant in vitro phenotypes with a sensitive, data-rich measurement system and expert interpretation. The platform is demonstrable capable of screening-level throughout providing a more complete assessment of cardiovascular efficay and safety with in vivo and clinical preditability.

Crescendo Biologics
Dr Laurie Galson-Holt
Director BD & IPDr Amanda You
Associate Director, Business Development
Cumulus
Meet Cumulus Neuroscience at the UK Pavilion (Hall B, Stand 2348).
Cumulus Neuroscience provides a reliable real-world multimodal digital data acquisition and analytics platform and end-to-end services and solutions for CNS clinical trials. Our platform is designed to be the gold-standard for CNS assessments, providing the critical data and insight needed for faster, more robust and cost-effective clinical trials that improve the delivery of new therapies to patients. We provide frequent at-home acquisition, combining neurophysiological monitoring (EEG) time-linked with a range of assessment tools, including cognition, mood, language and sleep. The frequent remote assessment significantly lowers patient burden and allows aggregation of multiple sessions to account for day-to-day cognitive fluctuation. Cumulus was formed in collaboration with leading global pharmaceutical companies to meet the industry’s complex clinical trial needs with a pharma advisory consortium, and Cumulus’ platform is currently deployed in clinical trials for neurodegeneration and neuropsychiatric diseases.

DLRC
Mr Kevin Judges
Director of Business Development and MarketingMr Greg Dombal
President, DLRC Inc
Domainex
Meet Domainex at the UK Pavilion (Hall B, Stand 2348).
Domainex is a multi-award-winning integrated drug discovery research service partner, which provides the full range of pre-clinical drug discovery services. We work collaboratively in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our team comprises of over 90 scientists, who are committed to providing high quality services, and have expertise in:
- Protein production and characterisation
- Structural biology: X-ray crystallography and cryo-EM
- Assay development and screening (biochemical, biophysical and cell assays)
- High-throughput screening (HTS)
- Computational chemistry including virtual screening
- Medicinal, synthetic and analytical chemistry
- Fragment- and structure-based drug discovery
We have an excellent reputation; >80% of our clients signed up for extensions or additional studies in 2022 and >95% stated they would recommend us to someone in their professional network.